Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Head and Neck Neoplasms 13Squamous Cell Carcinoma of Head and Neck 8Nasopharyngeal Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Salivary Gland Neoplasms 2Recurrence 2Osteosarcoma 2Optic Nerve Glioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasm Metastasis 2Melanoma 2Familial ependymoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Astrocytoma 2Wilms Tumor 1Thyroid Neoplasms 1Testicular Neoplasms 1Teratoma 1Spinocerebellar Degenerations 1

Interventions

pembrolizumab 8Radiotherapy 2Nivolumab 2Drug Therapy 2Biopsy 2pertuzumab 1liposomal doxorubicin 1cemiplimab 1cc-486 1brodalumab 1atezolizumab 1Trastuzumab 1Therapeutics 1Surveys and Questionnaires 1Semaxinib 1SUB1 protein, human 1Radiosurgery 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1Oxaliplatin 1Observation 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Lighting 1Isotretinoin 1Interleukin-2 1Interferon-alpha 1Injections 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × Oxaliplatin × Head & Neck × Clear all
NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

Phase 1 Active not recruiting
39 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡